Atrial Fibrillation

AFib Might Be Far More Common Than We Think

A JACC study suggests that atrial fibrillation is far more prevalent than many previously thought, estimating that nearly one in 20 American adults have been diagnosed with the disease.

UCSF researchers analyzed medical records from 29M adults who received hospital-based care in California from 2005 to 2019 (51yr avg. age, 54% women, 50% White), finding that a whopping 2M (6.8%) of them had been diagnosed with AFib.

  • AFib rates increased dramatically during the study period, from 4.49% in 2005-2009 to 6.82% in 2015-2019.
  • That increase was greatest among younger patients, males, minorities, and patients with hypertension and diabetes. 

When these results are applied across the U.S., the researchers estimate that at least 10.55M Americans are currently diagnosed with AFib, representing 4.48% the U.S. adult population.

  • That’s far higher than previous estimates, including a pair of JAMA and Circulation studies that estimated nationwide AFib rates of 2.26M and 5.1M back in 2000, and forecasted that 3.33M and 7.5M adults would have AFib by 2020.

Since all of these studies only looked at patients who were already diagnosed, true AFib prevalence is likely far higher, with the authors noting that wearable-based arrhythmia detection might drive far more significant diagnosis increases in the future.

The Takeaway

Although few readers are likely surprised that AFib diagnosis is on the rise, this study’s 51% growth rate and 4.48% prevalence estimate truly are shocking, and suggest that we might see a wave of AFib-related care in the future.

Get twice-weekly insights on the biggest stories shaping cardiology.

You might also like

Cardiovascular Disease August 4, 2025

The Impact of Physical Activity Before and After CV Events August 4, 2025

A long-term analysis of the CARDIA study revealed that moderate-to-vigorous physical activity steadily declines from young adulthood through midlife, but patients destined to develop cardiovascular disease experience rapid activity decreases more than a decade before their first event. Collecting data over 37 years, researchers tracked ~3k participants from young adulthood to middle age and paired […]

Cardiology Pharmaceuticals July 31, 2025

AstraZeneca’s Anselamimab Comes Up Short in Phase 3 Trial July 31, 2025

In a setback to one of its rarer disease pipelines, AstraZeneca’s amyloidosis antibody, anselamimab, failed to significantly reduce all-cause mortality and CV hospitalizations in the CARES Phase 3 trial’s overall patient population.  The CARES clinical program was the largest prospective cardiac AL amyloidosis investigation to date, enrolling 406 patients to test whether anselamimab could reduce […]

Cardiology Pharmaceuticals July 28, 2025

SGLT2i Prescriptions Increase for HF, With Some Exceptions July 28, 2025

Three years after SGLT2 inhibitors were added to the heart failure treatment guidelines, a JAMA Cardiology study reveals significant new prescriptions, with a few key patient sub-groups falling behind. Researchers analyzed prescribing patterns of SGLT2 inhibitors for 760k HF patients in the National Cardiovascular Data Registry and found significant and rapid uptake in the last […]

You might also like..

Select All

You're signed up!

It's great to have you as a reader. Check your inbox for a welcome email.

-- The Cardiac Wire Team

You're all set!